Sutro Biopharma to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery company, announces CEO Bill Newell's participation in two investor conferences. The Jefferies Healthcare Conference is on June 9, 2022, at 8:00 a.m. ET, in New York City, and the JMP Securities Life Sciences Conference will be held on June 16, 2022, at 9:30 a.m. ET. Both events will feature live webcasts accessible on Sutro's Investor Relations page, with archived replays available for 30 days post-event. Sutro focuses on developing next-generation cancer therapies using advanced protein engineering.

SOUTH SAN FRANCISCO, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (“Sutro” or the “Company”) (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer therapeutics, today announced that Chief Executive Officer, Bill Newell, will participate in two upcoming investor conferences.

Presentation Details:

Jefferies Healthcare Conference 
Format: Presentation
Date: Thursday, June 9, 2022
Time: 8:00 a.m. ET / 5:00 a.m. PT
Location: New York City

The JMP Securities Life Sciences Conference
Format: Fireside Chat
Date: Thursday, June 16, 2022
Time: 9:30 a.m. ET / 6:30 a.m. PT 
Location: New York City

Live webcasts of each presentation can be accessed through the Events and Presentations page of the Investor Relations section on the company’s website at www.sutrobio.com. Archived replays of the webcasts will be available on the company’s website for approximately 30 days following each live presentation.

About Sutro Biopharma

Sutro Biopharma, Inc., located in South San Francisco, is a clinical-stage drug discovery, development and manufacturing company. Using precise protein engineering and rational design, Sutro is advancing next-generation oncology therapeutics.

Sutro’s proprietary and integrated cell-free protein synthesis platform XpressCF® and site-specific conjugation platform XpressCF+™ led to the discovery of STRO-001 and STRO-002, Sutro’s first two internally-developed ADCs. STRO-001 is a CD74-targeting ADC currently under investigation in a Phase 1 clinical trial for patients with advanced B-cell malignancies and was granted Orphan Drug Designation by the FDA for multiple myeloma. STRO-002, a folate receptor alpha (FolRα)-targeting ADC, is currently being investigated in a Phase 1 clinical trial for patients with ovarian and endometrial cancers and was granted Fast Track designation by the FDA for ovarian cancer. A third product candidate, CC-99712, a BCMA-targeting ADC, which is part of Sutro’s collaboration with Bristol Myers Squibb, formerly Celgene Corporation, is enrolling patients for its Phase 1 clinical trial of patients with multiple myeloma and has received Orphan Drug Designation from the FDA. A fourth product candidate, M1231, a MUC1-EGFR, bispecific ADC, which is part of Sutro’s collaboration with Merck KGaA, Darmstadt, Germany, known as EMD Serono in the U.S. and Canada (EMD Serono), is enrolling patients for its Phase 1 clinical trial of patients with metastatic solid tumors, non-small cell lung cancer (NSCLC) and esophageal squamous cell carcinoma. These four product candidates resulted from Sutro’s XpressCF® and XpressCF+™ technology platforms. Bristol Myers Squibb and EMD Serono have worldwide development and commercialization rights for CC-99712 and M1231, respectively, for which Sutro is entitled to milestone or contingent payments and tiered royalties.

Sutro is dedicated to transforming the lives of cancer patients by creating medicines with improved therapeutic profiles for areas of unmet need. To date, Sutro’s platform has led to ADCs, bispecific antibodies, cytokine-based immuno-oncology therapies, and vaccines directed at precedented targets in clinical indications where the current standard of care is suboptimal.

Sutro’s platform allows it to accelerate discovery and development of potential first-in-class and best-in-class molecules through rapid and systematic evaluation of protein structure-activity relationships to create optimized homogeneous product candidates. In addition to developing its own oncology pipeline, Sutro is collaborating with select pharmaceutical and biotechnology companies to discover and develop novel, next-generation therapeutics.

Follow Sutro on Twitter, @Sutrobio, and at www.sutrobio.com to learn more about our passion for changing the future of oncology.

Investor & Media Contact
Annie J. Chang
Sutro Biopharma
(650) 801-5728
ajchang@sutrobio.com

Amy Bonanno
Solebury Trout
(914) 450-0349
abonanno@soleburytrout.com

FAQ

What are the details of Sutro Biopharma's investor conferences in June 2022?

Sutro Biopharma will participate in the Jefferies Healthcare Conference on June 9, 2022, at 8:00 a.m. ET, and the JMP Securities Life Sciences Conference on June 16, 2022, at 9:30 a.m. ET, both in New York City.

How can I access the webcasts of Sutro Biopharma's presentations?

Live webcasts of Sutro Biopharma's presentations can be accessed through the Events and Presentations section on their website, with archived replays available for approximately 30 days.

What is the focus of Sutro Biopharma's development efforts?

Sutro Biopharma focuses on clinical-stage drug discovery and developing next-generation cancer therapeutics using precise protein engineering.

What is STRO-001 and its current status?

STRO-001 is a CD74-targeting antibody-drug conjugate (ADC) currently undergoing a Phase 1 clinical trial for advanced B-cell malignancies and has received Orphan Drug Designation from the FDA for multiple myeloma.

What is STRO-002 and what trial is it part of?

STRO-002 is a folate receptor alpha-targeting ADC currently in a Phase 1 clinical trial for ovarian and endometrial cancers, having received Fast Track designation from the FDA for ovarian cancer.